Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Police say violent crime improving in downtown Raleigh, but more work is needed
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
Next >
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
November 10, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
November 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
November 01, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin’s EMBARK Program Announces Graduation of Facilitators
October 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin & The Chopra Foundation Recognize World Mental Health Day
October 10, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Update on its Intellectual Property Portfolio
October 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
September 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Upcoming Scientific and Investor Conferences
September 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
September 20, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Final Adelia Milestone Achievement
August 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
August 30, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Results of Shareholders’ Meeting
August 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 28, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Date of Annual Meeting of Shareholders
July 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
July 11, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievement
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
June 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
June 22, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Present at the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
June 16, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
June 09, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Acquires DMT Clinical Study from Entheon Biomedical
June 07, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Additional Adelia Milestone Achievements
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
June 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
June 02, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.